Generics Lawsuit Lupin Settles Lawsuit with Medicis

Editor: Dominik Stephan

Indian producer of generic drugs Lupin recently announced to have settled all ongoing litigations over generic versions of Solodyn, an anti-biotic used to treat acne.

(Picture: Lupin)
(Picture: Lupin)

Mumbai/India – Lupin's subsidiary Lupin Pharmaceuticals will market its generic Solodyn treatment in 45mg, 90mg, and 135mg strengths under a license from Medicis, beginning in November 2011. Lupin will also be able to sell generic versions of Solodyn in 65mg and 115mg strengths under a license from Medicis effective in February 2018.

Lupin also signed a research and development agreement with Medicis for multiple therapeutic compounds. The contract grants Medicis global rights (excluding India) for the products developed under the agreement. Lupin will be responsible for he development of a range of new therapeutic products recieving a total of US $ 38 million (Rs 1.65 billion).